ArticleScientific reports2026
Quantitative analysis of myeloid cell patterns and immunosuppressive enzyme (IDO, ARG1) expression in colorectal cancer pulmonary metastases and corresponding primary tumours.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Indoleamine-2,3-dioxygenase (IDO) and arginase1 (ARG1) are immunosuppressive enzymes frequently overexpressed in cancer, with higher expression in colorectal cancer primary tumours paradoxically linked to favourable survival. Their significance in metastases remains unexplored. Employing multiplexed immunohistochemistry and supervised machine learning-based digital image analysis, we analysed the IDO and ARG1 expression in monocytic cells, granulocytes, mast-cells and tumour cells in 91 resected pulmonary metastases from 53 corresponding primary tumours. We also evaluated the spatial distribution of IDO+ and ARG1+ cells relative to tumour cells and compared these patterns between metastases and primary tumours. In metastases, higher IDO+ monocytic cell densities in the tumour centre were associated with favourable survival (adjusted HR 0.17, 95%CI 0.05–0.59, p = 0.005), while higher IDO– monocytic cell densities in the invasive margins were associated with worse survival (adjusted HR 4.19, 95%CI 1.45–12.05, p = 0.008). Moreover, higher densities of IDO+HLA-DR− immature monocytic cells and IDO+FCGR3+ monocytic cells in the invasive margin were also associated with poor survival, after adjusting for T-cell densities (adjusted HRs 26.4, 95%CI 4.95 − 140.42, p < 0.001 and 3.91 95%CI 0.97 − 15.76, p = 0.056, respectively). These findings provide detailed insights into the immunosuppressive myeloid cell landscape in colorectal cancer pulmonary metastases, highlighting key differences from primary tumours and potential implications for therapy development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.